CoChat
Cited by 215

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Melatonin in Alzheimer’s Disease

Open access
Lin, Li, Huang, Qiong-Xia, Yang, Shu-Sheng, Chu, Jiang, Wang, Jian-Zhi, Tian, Qing · 2013 · International Journal of Molecular Sciences

Abstract

Alzheimer’s disease (AD), an age-related neurodegenerative disorder with progressive cognition deficit, is characterized by extracellular senile plaques (SP) of aggregated β-amyloid (Aβ) and intracellular neurofibrillary tangles, mainly containing the hyperphosphorylated microtubule-associated protein tau. Multiple factors contribute to the etiology of AD in terms of initiation and progression. Melatonin is an endogenously produced hormone in the brain and decreases during aging and in patients with AD. Data from clinical trials indicate that melatonin supplementation improves sleep, ameliorates sundowning and slows down the progression of cognitive impairment in AD patients. Melatonin efficiently protects neuronal cells from Aβ-mediated toxicity via antioxidant and anti-amyloid properties. It not only inhibits Aβ generation, but also arrests the formation of amyloid fibrils by a structure-dependent interaction with Aβ. Our studies have demonstrated that melatonin efficiently attenuates Alzheimer-like tau hyperphosphorylation. Although the exact mechanism is still not fully understood, a direct regulatory influence of melatonin on the activities of protein kinases and protein phosphatases is proposed. Additionally, melatonin also plays a role in protecting the cholinergic system and in anti-inflammation. The aim of this review is to stimulate interest in melatonin as a potentially useful agent in the prevention and treatment of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms140714575

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 128

  1. Lars, 2011, Amyloid-β and tau—A toxic pas de deux in Alzheimer’s disease, Nat. Rev. Neurosci, 12, 67, 10.1038/nrn2967 · DOI · Paper page
  2. Mustapic, 2012, Alzheimer’s disease and type 2 diabetes: The association study of polymorphisms in tumor necrosis factor-alpha and apolipoprotein E genes, Metab. Brain Dis, 27, 507, 10.1007/s11011-012-9310-1 · DOI
  3. Ajala, T., Rafi, J., Wray, R., Whitehead, M.W., and Zaidi, J. (2009). There may be a link between intrahepatic cholestasis of pregnancy and familial combined hyperlipidaemia: A case report. Cases J., 2. · DOI
  4. Leszek, 2012, Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer’s disease, J. Neurol. Sci, 323, 25, 10.1016/j.jns.2012.09.010 · DOI
  5. Rocchi, 2012, NMR metabolomic investigation of astrocytes interacted with Abeta(42) or its complexes with either copper(II) or zinc(II), J. Inorg. Biochem, 117, 326, 10.1016/j.jinorgbio.2012.08.021 · DOI
  6. Rukhsana, 2010, Role of oxidative stress in the progression of Alzheimer’s disease, J. Alzheimers Dis, 19, 341, 10.3233/JAD-2010-1222 · DOI · Paper page
  7. Wu, 2005, The human pineal gland and melatonin in aging and Alzheimer’s disease, J. Pineal Res, 38, 145, 10.1111/j.1600-079X.2004.00196.x · DOI · Paper page
  8. Wu, 2003, Molecular changes underlying reduced pineal melatonin levels in Alzheimer’s disease: Alterations in preclinical and clinical stages, J. Clin. Endocr. Metab, 88, 5898, 10.1210/jc.2003-030833 · DOI · Paper page
  9. Ferrari, 2000, Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia, Exp. Gerontol, 35, 1239, 10.1016/S0531-5565(00)00160-1 · DOI
  10. Ohashi, 1999, Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer’s type, Biol. Psychiat, 45, 1646, 10.1016/S0006-3223(98)00255-8 · DOI
  11. Zhou, 2003, Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels, J. Pineal Res, 35, 125, 10.1034/j.1600-079X.2003.00065.x · DOI · Paper page
  12. Savaskan, 2002, Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer’s disease patients, J. Pineal Res, 32, 59, 10.1034/j.1600-079x.2002.00841.x · DOI
  13. Savaskan, 2005, Reduced hippocampal MT2 melatonin receptor expression in Alzheimer’s disease, J. Pineal Res, 38, 10, 10.1111/j.1600-079X.2004.00169.x · DOI · Paper page
  14. Friedland, 1990, A quantitative study of intracranial calcification in dementia of the Alzheimer’s type, Int. Psychogeriatr, 2, 36, 10.1017/S104161029000028X · DOI
  15. Wu, 2007, A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer’s disease patients, Brain Res, 1167, 13, 10.1016/j.brainres.2007.06.053 · DOI
  16. Garfinkel, 2000, Melatonin for treatment of sundowning in elderly persons with dementia—A preliminary study, Arch. Gerontol. Geriatr, 31, 65, 10.1016/S0167-4943(00)00068-6 · DOI · Paper page
  17. Brusco, 2000, Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer’s disease, Neuro Endocrinol. Lett, 21, 39
  18. Brusco, 1998, Monozygotic twins with Alzheimer’s disease treated with melatonin: Case report, J. Pineal Res, 25, 260, 10.1111/j.1600-079X.1998.tb00396.x · DOI · Paper page
  19. Cardinali, 2002, Melatonin in sleep disorders and jet-lag, Neuro Endocrinol. Lett, 23, 9
  20. Cardinali, 2002, The use of melatonin in Alzheimer’s disease, Neuro Endocrinol. Lett, 23, 20
  21. Karasek, 2002, Future of melatonin as a therapeutic agent, Neuro Endocrinol. Lett, 23, 118
  22. Ling, 2009, Constant illumination induces Alzheimer-like damages with endoplasmic reticulum involvement and the protection of melatonin, J. Alzheimers Dis, 16, 287, 10.3233/JAD-2009-0949 · DOI
  23. Brion, 2001, Neurofibrillary tangles and tau phosphorylation, Biochem. Soc. Symp, 67, 81, 10.1042/bss0670081 · DOI
  24. Billingsley, 1997, Regulated phosphorylation and dephosphorylation of tau protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneration, Biochem. J, 323, 577, 10.1042/bj3230577 · DOI · Paper page
  25. Braak, 1994, A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads, Acta Neuropathol, 87, 554, 10.1007/BF00293315 · DOI · Paper page
  26. Avila, 2004, Assembly in vitro of tau protein and its implications in Alzheimer’s disease, Curr. Alzheimer’s Res, 1, 97, 10.2174/1567205043332207 · DOI
  27. Sahara, 2013, Characteristics of TBS-extractable hyperphosphorylated Tau species: Aggregation intermediates in rTg4510 mouse brain, J. Alzheimers Dis, 33, 249, 10.3233/JAD-2012-121093 · DOI
  28. Khatoon, 1992, Brain levels of microtubule-associated protein tau are elevated in Alzheimer’s disease: A radioimmuno-slot-blot assay for nanograms of the protein, J. Neurochem, 59, 750, 10.1111/j.1471-4159.1992.tb09432.x · DOI · Paper page
  29. Khatoon, 1994, Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer’s disease and control brains, FEBS Lett, 351, 80, 10.1016/0014-5793(94)00829-9 · DOI · Paper page
  30. Hanger, 1998, New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer’s disease brain using nanoelectrospray mass spectrometry, J. Neurochem, 71, 2465, 10.1046/j.1471-4159.1998.71062465.x · DOI · Paper page
  31. Hasegawa, 1995, Hyperphosphorylation of tau in PHF, Neurobiol. Aging, 16, 365, 10.1016/0197-4580(95)00027-C · DOI · Paper page
  32. Wang, 2008, Human tau protein forms complex with PrP and some GSS- and fCJD-related PrP mutants possess stronger binding activities with tau in vitro, Mol. Cell. Biochem., 310, 49, 10.1007/s11010-007-9664-6 · DOI
  33. Peng, 2013, Disease-modified glycogen synthase kinase-3beta intervention by melatonin arrests the pathology and memory deficits in an Alzheimer’s animal model, Neurobiol. Aging, 34, 1555, 10.1016/j.neurobiolaging.2012.12.010 · DOI
  34. Deng, 2005, Effects of melatonin on wortmannin-induced tau hyperphosphorylation, Acta Pharmacol. Sin, 26, 519, 10.1111/j.1745-7254.2005.00102.x · DOI
  35. Li, 2005, Effect of melatonin on calyculin A-induced tau hyperphosphorylation, Eur. J. Pharmacol, 510, 25, 10.1016/j.ejphar.2005.01.023 · DOI
  36. Li, 2004, Melatonin protects SH-SY5Y neuroblastoma cells from calyculin A-induced neurofilament impairment and neurotoxicity, J. Pineal Res, 36, 186, 10.1111/j.1600-079X.2004.00116.x · DOI
  37. Yang, 2011, Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A, J. Psychopharmacol, 25, 1118, 10.1177/0269881110367723 · DOI
  38. Wang, 2004, Melatonin ameliorated okadaic-acid induced Alzheimer-like lesions, Acta Pharmacol. Sin, 25, 276
  39. Liu, 2002, Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin, Acta Pharmacol. Sin, 23, 183
  40. Wang, 2004, Melatonin attenuates isoproterenol-induced protein kinase A overactivation and tau hyperphosphorylation in rat brain, J. Pineal Res, 37, 11, 10.1111/j.1600-079X.2004.00130.x · DOI
  41. Wang, 2005, Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat, Acta Pharmacol. Sin, 57, 7
  42. Avila, 2000, Tau aggregation into fibrillar polymers: Taupathies, FEBS Lett, 476, 89, 10.1016/S0014-5793(00)01676-8 · DOI
  43. Zhu, 2004, Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat, J. Pineal Res, 37, 71, 10.1111/j.1600-079X.2004.00136.x · DOI
  44. Reiter, 2001, Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system, Ann. N. Y. Acad. Sci, 939, 200, 10.1111/j.1749-6632.2001.tb03627.x · DOI · Paper page
  45. Smith, 2003, Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells, J. Neurosci. Res, 71, 863, 10.1002/jnr.10525 · DOI
  46. Lovell, 2004, Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3, J. Alzheimers Dis, 6, 659, 10.3233/JAD-2004-6610 · DOI · Paper page
  47. Kenyon, 2010, The genetics of ageing, Nature, 464, 504, 10.1038/nature08980 · DOI · Paper page
  48. Paradies, 2010, Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease, J. Pineal Res, 48, 297, 10.1111/j.1600-079X.2010.00759.x · DOI · Paper page
  49. Romero, 2010, Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells, J. Pineal Res, 49, 141, 10.1111/j.1600-079X.2010.00778.x · DOI
  50. Hardeland, 2009, Kynuramines, metabolites of melatonin and other indoles: The resurrection of an almost forgotten class of biogenic amines, J. Pineal Res, 47, 109, 10.1111/j.1600-079X.2009.00701.x · DOI · Paper page
  51. Jou, 2010, Visualization of melatonin’s multiple mitochondrial levels of protection against mitochondrial Ca(2+)-mediated permeability transition and beyond in rat brain astrocytes, J. Pineal Res, 48, 20, 10.1111/j.1600-079X.2009.00721.x · DOI · Paper page
  52. Hong, 2010, Melatonin plus exercise-based neurorehabilitative therapy for spinal cord injury, J. Pineal Res, 49, 201, 10.1111/j.1600-079X.2010.00786.x · DOI
  53. Das, 2010, The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors, J. Pineal Res, 48, 157, 10.1111/j.1600-079X.2009.00739.x · DOI
  54. Schuster, 2005, The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway, J. Neuroendocrinol, 17, 170, 10.1111/j.1365-2826.2005.01288.x · DOI
  55. Peschke, 2002, Receptor (MT(1)) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1, J. Pineal Res, 33, 63, 10.1034/j.1600-079X.2002.02919.x · DOI
  56. MacKenzie, 2000, Melatonin induction of filamentous structures in non-neuronal cells that is dependent on expression of the human mt1 melatonin receptor, Cell Motil. Cytoskeleton, 46, 28, 10.1002/(SICI)1097-0169(200005)46:1<28::AID-CM4>3.0.CO;2-5 · DOI
  57. Gerdin, 2003, Regulation of basal rhythmicity in protein kinase C activity by melatonin in immortalized rat suprachiasmatic nucleus cells, Neurosci. Lett, 346, 37, 10.1016/S0304-3940(03)00590-1 · DOI
  58. Rios, 1996, In vitro inhibition of Ca2+/calmodulin-dependent kinase II activity by melatonin, Biochim. Biophys. Acta, 1290, 191, 10.1016/0304-4165(96)00025-6 · DOI
  59. Chen, 2011, CaMKII is involved in cadmium activation of MAPK and mTOR pathways leading to neuronal cell death, J. Neurochem, 119, 1108, 10.1111/j.1471-4159.2011.07493.x · DOI
  60. Chan, 2002, Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins, Cell. Signal, 14, 249, 10.1016/S0898-6568(01)00240-6 · DOI
  61. Chen, 2011, Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death, Free Radic. Biol. Med, 50, 624, 10.1016/j.freeradbiomed.2010.12.032 · DOI · Paper page
  62. Xu, 2011, Calcium signaling is involved in cadmium-induced neuronal apoptosis via induction of reactive oxygen species and activation of MAPK/mTOR network, PLoS One, 6, e19052, 10.1371/journal.pone.0019052 · DOI · Paper page
  63. Selkoe, 1998, The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer’s disease, Trends Cell Biol, 8, 447, 10.1016/S0962-8924(98)01363-4 · DOI · Paper page
  64. Fisher, 2003, M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease: Implications in future therapy, J. Mol. Neurosci, 20, 349, 10.1385/JMN:20:3:349 · DOI
  65. Lahiri, 1999, Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types, J. Pineal Res, 26, 137, 10.1111/j.1600-079X.1999.tb00575.x · DOI
  66. Lahiri, 2004, Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex, J. Pineal Res, 36, 224, 10.1111/j.1600-079X.2004.00121.x · DOI
  67. Song, 1997, Melatonin alters the metabolism of the beta-amyloid precursor protein in the neuroendocrine cell line PC12, J. Mol. Neurosci, 9, 75, 10.1007/BF02736852 · DOI
  68. Zhang, 2004, Melatonin attenuates beta-amyloidinduced inhibition of neurofilament expression, Acta Pharmacol. Sin, 25, 447
  69. Olivieri, 2001, Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion, J. Pineal Res, 31, 320, 10.1034/j.1600-079X.2001.310406.x · DOI
  70. Wang, 2008, Effect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells, Neurochem. Res, 33, 1138, 10.1007/s11064-007-9563-y · DOI
  71. Quinn, 2005, Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: Implications for clinical trials, Brain Res, 1037, 209, 10.1016/j.brainres.2005.01.023 · DOI
  72. Hsiao, 1996, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, Science, 274, 99, 10.1126/science.274.5284.99 · DOI · Paper page
  73. Su, 2004, Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing, Biochemistry, 43, 6899, 10.1021/bi035627j · DOI · Paper page
  74. Ryder, 2003, Divergent roles of GSK-3 and CDK5 in APP processing, Biochem. Biophys. Res. Commun, 312, 922, 10.1016/j.bbrc.2003.11.014 · DOI
  75. Phiel, 2003, GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides, Nature, 423, 435, 10.1038/nature01640 · DOI · Paper page
  76. Donnelly, 2008, Selective intracellular release of copper and zinc ions from bis (thiosemicarbazonato) complexes reduces levels of Alzheimer’s disease amyloid-beta peptide, J. Biol. Chem, 283, 4568, 10.1074/jbc.M705957200 · DOI · Paper page
  77. Tesco, 2000, GSK-3 beta forms a tetrameric complex with endogenous PS1-CTF/NTF and beta-catenin. Effects of the D257/D385A and FAD-linked mutations, Ann. N. Y. Acad. Sci, 920, 227, 10.1111/j.1749-6632.2000.tb06927.x · DOI
  78. Takashima, 1998, Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau, Proc. Natl. Acad. Sci. USA, 95, 9637, 10.1073/pnas.95.16.9637 · DOI · Paper page
  79. Simmons, 1994, Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro, Mol. Pharmacol, 45, 373
  80. Soto, 1996, The conformation of Alzheimer’s beta peptide determines the rate of amyloid formation and its resistance to proteolysis, Biochem. J, 314, 701, 10.1042/bj3140701 · DOI
  81. Poeggeler, 2001, Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer’s amyloid Abeta peptide, Biochemistry, 40, 14995, 10.1021/bi0114269 · DOI
  82. Skribanek, 2001, Interaction between synthetic amyloid-beta-peptide (1–40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry, J. Mass Spectrom, 36, 1226, 10.1002/jms.243 · DOI
  83. Pappolla, 1998, Inhibition of Alzheimer’s beta-fibrillogenesis by melatonin, J. Biol. Chem, 273, 7185, 10.1074/jbc.273.13.7185 · DOI · Paper page
  84. Huang, 1997, Fibrillogenesis of Alzheimer’s Abeta peptides studied by fluorescence energy transfer, J. Mol. Biol, 269, 214, 10.1006/jmbi.1997.1050 · DOI
  85. Fraser, 1991, pH-dependent structural transitions of Alzheimer’s amyloid peptides, Biophys. J, 60, 1190, 10.1016/S0006-3495(91)82154-3 · DOI · Paper page
  86. Masilamoni, 2008, The neuroprotective role of melatonin against amyloid beta peptide injected mice, Free Radic. Res, 42, 661, 10.1080/10715760802277388 · DOI
  87. Pacchierotti, 2001, Melatonin in psychiatric disorders: A review on the melatonin involvement in psychiatry, Front. Neuroendocrin, 22, 18, 10.1006/frne.2000.0202 · DOI · Paper page
  88. Yuan, 1991, [125I]Iodomelatonin-binding sites in the pigeon brain: Binding characteristics, regional distribution and diurnal variation, J. Endocrinol., 128, 475, 10.1677/joe.0.1280475 · doi:10.1677/joe.0.1280475
  89. Bieschke, 2005, Oxidative metabolites accelerate Alzheimer’s amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation, Biochemistry, 44, 4977, 10.1021/bi0501030 · DOI
  90. Feng, 2004, Protective effect of melatonin on beta-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism, Free Radic. Biol. Med, 37, 1790, 10.1016/j.freeradbiomed.2004.08.023 · DOI
  91. Zatta, 2003, Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metalions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)], J. Pineal Res, 35, 98, 10.1034/j.1600-079X.2003.00058.x · DOI
  92. Feng, 2004, Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer’s disease, J. Pineal Res, 37, 129, 10.1111/j.1600-079X.2004.00144.x · DOI · Paper page
  93. Shen, 2002, The protective effects of melatonin from oxidative damage induced by amyloid beta-peptide 25–35 in middle-aged rats, J. Pineal Res, 32, 85, 10.1034/j.1600-079x.2002.1819.x · DOI
  94. Tan, 2003, Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid-beta peptide in rat brain: a comparative, in vivo study versus vitamin C and E, J. Pineal Res, 35, 80, 10.1034/j.1600-079X.2003.00057.x · DOI
  95. Slats, 2013, Reciprocal interactions between sleep, circadian rhythms and Alzheimer’s disease: Focus on the role of hypocretin and melatonin, Ageing Res. Rev, 12, 188, 10.1016/j.arr.2012.04.003 · DOI
  96. Rothman, 2012, Sleep disturbances in Alzheimer’s and Parkinson’s diseases, Neuromolecular Med, 14, 194, 10.1007/s12017-012-8181-2 · DOI · Paper page
  97. Cecon, 2011, Relevance of the chronobiological and non-chronobiological actions of melatonin for enhancing therapeutic efficacy in neurodegenerative disorders, Recent Pat. Endocr. Metab. Immune Drug Discov, 5, 91, 10.2174/187221411799015381 · doi:10.2174/187221411799015381
  98. Kang, 2009, Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle, Science, 326, 1005, 10.1126/science.1180962 · DOI · Paper page
  99. Struble, 1982, Cholinergic innervation in neuritic plaques, Science, 216, 413, 10.1126/science.6803359 · DOI · Paper page
  100. Coyle, 1983, Alzheimer’s disease: A disorder of cortical cholinergic innervation, Science, 219, 1184, 10.1126/science.6338589 · DOI · Paper page
  101. Rasool, 1986, Neurofibrillary degeneration of cholinergic and noncholinergic neurons of the basal forebrain in Alzheimer’s disease, Ann. Neurol, 20, 482, 10.1002/ana.410200407 · DOI
  102. Samuel, 1994, Hippocampal connectivity and Alzheimer’s dementia: Effects of synapse loss and tangle frequency in a two-component model, Neurology, 44, 2081, 10.1212/WNL.44.11.2081 · DOI
  103. Davis, 1999, Cholinergic markers in elderly patients with early signs of Alzheimer’s disease, J. Am. Med. Assoc, 281, 1401, 10.1001/jama.281.15.1401 · DOI · Paper page
  104. Rinne, 2003, Semantic decision making in early probable AD: A PET activation study, Cogn. Brain Res, 18, 89, 10.1016/j.cogbrainres.2003.09.009 · DOI
  105. Spencer, 2010, Investigation into the efficacy of the acetylcholinesterase inhibitor, donepezil, and novel procognitive agents to induce gamma oscillations in rat hippocampal slices, Neuropharmacology, 59, 437, 10.1016/j.neuropharm.2010.06.005 · DOI
  106. Guermonprez, 2001, Inhibition of acetylcholine synthesis and tyrosine nitration induced by peroxynitrite are differentially prevented by antioxidants, Mol. Pharmacol, 60, 838
  107. Feng, 2004, Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats, J. Pineal Res, 37, 198, 10.1111/j.1600-079X.2004.00158.x · DOI
  108. Tang, 2002, The effects of melatonin and Ginkgo biloba extract on memory loss and choline acetyltransferase activities in the brain of rats infused intracerebroventricularly with beta-amyloid 1–40, Life Sci, 71, 2625, 10.1016/S0024-3205(02)02105-7 · DOI
  109. Agrawal, 2009, A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia, Neuropharmacology, 56, 779, 10.1016/j.neuropharm.2009.01.005 · DOI · Paper page
  110. Hansen, 2008, Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis, Clin. Interv. Aging, 3, 211
  111. Cardinali, 2010, Clinical aspects of melatonin intervention in Alzheimer’s disease progression, Curr. Neuropharmacol, 8, 218, 10.2174/157015910792246209 · DOI · Paper page
  112. Perez, 2009, Tacrine-melatonin hybrids as multifunctional agents for Alzheimer’s disease, with cholinergic, antioxidant, and neuroprotective properties, ChemMedChem, 4, 828, 10.1002/cmdc.200800414 · DOI · Paper page
  113. Spuch, 2010, A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer’s disease, Neurotox. Res, 17, 421, 10.1007/s12640-009-9121-2 · DOI
  114. Arends, 2000, Microglia, amyloid and dementia in Alzheimer’s disease. A correlative study, Neurobiol. Aging, 21, 39, 10.1016/S0197-4580(00)00094-4 · DOI · Paper page
  115. Stuchbury, 2005, Alzheimer’s associated inflammation, potential drug targets and future therapies, J. Neural. Transm, 112, 429, 10.1007/s00702-004-0188-x · DOI
  116. Tuppo, 2005, The role of inflammation in Alzheimer’s disease, Int. J. Biochem. Cell B, 37, 289, 10.1016/j.biocel.2004.07.009 · DOI · Paper page
  117. Park, 2012, Anti-inflammatory effects of aromatic-turmerone through blocking of NF-kappaB, JNK, and p38 MAPK signaling pathways in amyloid beta-stimulated microglia, Int. Immunopharmacol, 14, 13, 10.1016/j.intimp.2012.06.003 · DOI
  118. Chung, 2003, Melatonin attenuates kainic acid-induced hippocampal neurodegeneration and oxidative stress through microglial inhibition, J. Pineal Res, 34, 95, 10.1034/j.1600-079X.2003.00010.x · DOI
  119. Mohan, 1995, The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B, Biochem. Mol. Biol. Int, 37, 1063
  120. Chuang, 1996, Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen, Cell Biol. Int, 20, 687, 10.1006/cbir.1996.0091 · DOI
  121. Lau, 2012, Interleukin-6 autocrine signaling mediates melatonin MT(1/2) receptor-induced STAT3 Tyr(705) phosphorylation, J. Pineal Res, 52, 477, 10.1111/j.1600-079X.2011.00965.x · DOI
  122. Shen, 2007, Suppressive effects of melatonin on amyloid-beta-induced glial activation in rat hippocampus, Arch. Med. Res, 38, 284, 10.1016/j.arcmed.2006.10.007 · DOI
  123. Grases, 2010, A potential role for crystallization inhibitors in treatment of Alzheimer’s disease, Med. Hypoth, 74, 118, 10.1016/j.mehy.2009.07.029 · DOI
  124. Wollen, 2010, Alzheimer’s disease: The pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners, J. Clin. Ther, 15, 223
  125. Dowling, 2008, Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer’s disease, J. Am. Geriatr. Soc, 56, 239, 10.1111/j.1532-5415.2007.01543.x · DOI · Paper page
  126. Pappolla, 2000, An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: Implications for Alzheimer’s disease, J. Neural. Transm, 107, 203, 10.1007/s007020050018 · DOI · Paper page
  127. Nagtegaal, 1996, Melatonin: A survey of suspected adverse drug reactions, Sleep-Wake Res. Netherl, 7, 115
  128. Avery, 1998, Guidelines for prescribing melatonin, Ann. Med, 30, 122, 10.3109/07853899808999394 · DOI

Cited by

Metadata

Authors
Lin, L., Huang, Q.-X., Yang, S.-S., Chu, J., Wang, J.-Z., & Tian, Q.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2013-07-12
Volume
14
Issue
7
Pages
14575-14593
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2162142126
Cited by
215
References
17
FWCI
13.06
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.